Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company developing innovative therapeutics using its proprietary bicyclic peptide technology, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 19, 2024, at 10:30 a.m. GMT. Investors and interested parties can access a live webcast of the presentation through the company's website, with a replay available after the event.
Bicycle Therapeutics (NASDAQ: BCYC), una compagnia farmaceutica che sviluppa terapie innovative utilizzando la propria tecnologia dei peptidi biciclici, ha annunciato la sua partecipazione alla prossima Conferenza Sanitaria di Jefferies a Londra. La direzione dell'azienda parteciperà a una chiacchierata informale il 19 novembre 2024, alle 10:30 ora GMT. Gli investitori e gli interessati possono accedere a una diretta streaming della presentazione tramite il sito web dell'azienda, con una registrazione disponibile dopo l'evento.
Bicycle Therapeutics (NASDAQ: BCYC), una compañía farmacéutica que desarrolla terapias innovadoras utilizando su tecnología de péptidos bicíclicos, ha anunciado su participación en la próxima Conferencia de Salud de Jefferies en Londres. La dirección de la empresa participará en un chat informal el 19 de noviembre de 2024, a las 10:30 a.m. GMT. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de la compañía, con una repetición disponible después del evento.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 자사의 이중 고리 펩타이드 기술을 활용해 혁신적인 치료제를 개발하는 제약회사로, 제퍼리스 런던 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. 회사의 경영진은 2024년 11월 19일 오전 10시 30분 GMT에 비공식 토크에 참여할 예정입니다. 투자자와 관심 있는 분들은 회사 웹사이트를 통해 발표의 실시간 웹캐스트를 접속할 수 있으며, 행사 후에 재생이 가능합니다.
Bicycle Therapeutics (NASDAQ: BCYC), une société pharmaceutique développant des thérapies innovantes avec sa technologie des peptides bicycliques, a annoncé sa participation à la prochaine Conférence de Santé de Jefferies à Londres. La direction de l'entreprise participera à une discussion informelle le 19 novembre 2024, à 10h30 GMT. Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via le site web de l'entreprise, avec un replay disponible après l'événement.
Bicycle Therapeutics (NASDAQ: BCYC), ein Pharmaunternehmen, das innovative therapeutische Ansätze mit seiner eigenen technologie der bicyclischen Peptide entwickelt, hat seine Teilnahme an der bevorstehenden Jefferies London Healthcare Conference angekündigt. Das Management des Unternehmens wird am 19. November 2024 um 10:30 Uhr GMT an einem informellen Gespräch teilnehmen. Investoren und interessierte Parteien können über die Website des Unternehmens auf einen Live-Stream der Präsentation zugreifen, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- None.
- None.
A live webcast of the fireside chat will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112917062/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
When is Bicycle Therapeutics (BCYC) presenting at the Jefferies London Healthcare Conference?
How can investors watch Bicycle Therapeutics' (BCYC) presentation at the Jefferies conference?
Will there be a replay available of Bicycle Therapeutics' (BCYC) Jefferies conference presentation?
What type of presentation will Bicycle Therapeutics (BCYC) give at the Jefferies Healthcare Conference?
